Well, that didn’t take long. Turing Pharamaceuticals’ attempt to cash in on de facto (though not de jure) monopoly status as a provider of Daraprim has elicited competition from Imprimis, which aims to offer Daraprim users a close substitute for a dollar a pill. Turing CEO Martin Shkreli’s name will be forgotten in 5, 4, 3, … >>>
LINK: Drug with rage-inducing >5,000% price-hike now has $1/pill competitor (by Beth Mole for ArsTechnica)
Turing Pharmaceuticals, the company that last month raised the price of the decades-old drug Daraprim from $13.50 a pill to $750, now has a competitor.
Imprimis Pharmaceuticals, Inc., a specialty pharmaceutical company based in San Diego, announced today that it has made an alternative to Daraprim that costs about a buck a pill—or $99 for a 100-pill supply.
What do you think?
Brought to you by:
Business Ethics Highlights 
Pingback: Martin Shkreli, Stock Manipulation: Victimless Crimes (or Crimeless Victims?) |